Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Kyowa Kirin Co., Ltd.

4151

----

OverviewOverview NewsNews PostsPosts

LongbridgeAI

Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Pharmaceutical Technology·Jul 22 at 04:41 AM
4151
EU approves Kyowa Kirin’s Crysvita for infants with XLH
PUBT·Jul 21 at 02:00 AM
4151
10:31 ETSystemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
prnewswire·Jul 9 at 09:31 AM
NVS+0.71%BIIB-1.01%
How Investors Are Reacting To Kyowa Kirin (TSE:4151) Real-World Data On Mogamulizumab’s Patient Benefits
Simplywall·Jun 30 at 11:12 AM
4151
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML | KURA Stock News
StockTitan·Jun 10 at 11:02 PM
4151 KURA-2.31%
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML | KURA Stock News
StockTitan·Jun 1 at 11:32 PM
KURA-2.31%4151
Is Kyowa Kirin (TSE:4151) Pricing Reflect Its Mixed Long Term Share Performance
Simplywall·May 17 at 05:07 AM
4151
Kyowa Kirin secures FDA approval for Crysvita dosing update
Pharmaceutical Technology·May 15 at 03:42 AM
4151
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | KURA Stock News
StockTitan·May 12 at 12:40 AM
4151 KURA-2.31%
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
WorldPharmaceuticals·Apr 27 at 05:32 AM
KURA-2.31%4151